

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

2 - 8 February 2026



A new catalogue of industries encouraging foreign investment to take effect

With the approval of the State Council of China, the National Development and Reform Commission and the Ministry of Commerce jointly released the "Catalogue of Industries Encouraging Foreign Investment (2025 Edition)". The chemical new materials sector is one of the core areas encouraged by the policy, covering a large number of key sub-categories such as butadiene rubber, polyphenylene sulfide (PPS). **(ChemNet Chemical Industry Headlines)**

Longpan Technology builds 240,000-ton production base

Longpan Technology announced its expansion plan, intending to invest in the construction of a research and development center and a 240,000-ton-per-year high-pressure lithium iron phosphate production base in the Jintan Hualuogeng High-tech Industrial Development Zone, Jiangsu Province, with a planned total investment of no more than 2 billion yuan (€0.24 billion). **(ChemNet Chemical Industry Headlines)**

Bangpu Times: 450,000-ton project commences production

Bangpu Times' 450,000-ton/year new-generation lithium iron phosphate project in Yichang, Hubei Province, officially commenced production. As a core sub-project of the CATL-Bangpu integrated industrial park, and Bangpu's first strategic project using fourth-generation lithium iron phosphate technology, the project represents a total investment of 5.6 billion yuan (€0.68 billion). **(ChemNet Chemical Industry Headlines)**

China ranks 2nd globally in new drug development

China ranks second globally in new drug development, according to the National Health Commission. Domestically developed cancer drugs have been approved at home and abroad, and local HPV (Human Papillomavirus) vaccines are widely used. Advanced medical devices, including surgical robots and proton therapy systems, are in clinical use. **(China Daily)**

China blazing trail with novel drugs

China now accounts for 20% of novel pharmaceuticals worldwide. Multiple innovative cancer drugs, such as Zanubrutinib, have gained market approval domestically and abroad. The first domestic HPV vaccine protecting against nine virus strains has also been rolled out, enhancing accessibility. Additionally, advanced medical devices, including surgical robots and high-resolution CT scanners, have been developed. **(China Daily)**